Welcome

Dear Colleagues,

On June 5, 2008, Cambridge Major Laboratories broke ground on a new state-of-the-art large scale Active Pharmaceutical Ingredient (API) manufacturing site next to our headquarters in Germantown, Wisconsin, U.S. This new site will accommodate several of our current API manufacturing processes which are approaching commercial scale (100 kg’s to metric tons). The added manufacturing capabilities will also de-bottleneck existing pilot plants at our Germantown development facility.

The new site will be the premier, large scale pharmaceutical manufacturing site in the U.S. This expansion is in response to the company’s rapid growth at the Germantown and Dutch sites. Once completed (in the second half of 2009), the company will employ over 200 employees at 4 sites in the U.S. and Europe.

This “against the grain” move, positions CML into a narrow league of CRO/CMO’s capable of carrying out seamless API development from discovery/development to full commercialization.

In addition to our large scale expansion in the U.S., we have completed a major expansion in Europe, doubling the number of process R&D and GMP kilo laboratories, as well as enhancing our pilot plant and adding more analytical capability. The Weert facility is a premier API chemical development site located in the heart of Europe.

With much pride, I can say that Cambridge Major’s stated mission is to be the number one Western-based supplier of chemistry services to the pharma and biotech industries. The breadth and depth of qualified and experienced professionals insures excellence in our problem solving abilities, and supports our outstanding record for project execution and delivery.

President and CEO

Cambridge Major Laboratories Inc.